ODI Pharma AB (publ) (NGM:ODI)
Sweden · Delayed Price · Currency is SEK 2.420
-0.220 (-8.33%)
At close: Aug 14, 2026
ODI Pharma AB Revenue
ODI Pharma AB had revenue of 12.71M SEK in the quarter ending March 31, 2026, with 333.22% growth. This brings the company's revenue in the last twelve months to 29.82M, up 182.05% year-over-year. In the fiscal year ending June 30, 2025, ODI Pharma AB had annual revenue of 3.13M, down -85.94%.
Revenue (ttm)
29.82M
Revenue Growth
+182.05%
P/S Ratio
1.49
Revenue / Employee
29.82M
Employees
1
Market Cap
44.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.13M | -19.15M | -85.94% |
| Jun 30, 2024 | 22.29M | 22.15M | 15,880.34% |
| Jun 30, 2023 | 139.46K | -173.48K | -55.44% |
| Jun 30, 2022 | 312.94K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ABAS Protect AB | 86.43M |
| GreenMerc AB | 17.24M |
| LightAir AB | 14.43M |
| Kvix AB | 13.01M |
| Nattaro Labs AB | 6.04M |
| Zoomability Int AB | 3.24M |
| Synexo Group AB | 2.81M |
| Katalysen Ventures AB | 2.68M |
ODI Pharma AB News
- 2 months ago - ODI Pharma AB Quarterly report: Q3 2026 - Filings
- 6 months ago - ODI Pharma AB Quarterly report: Q2 2026 - Filings
- 9 months ago - ODI Pharma AB Quarterly report: Q1 2026 - Filings
- 1 year ago - ODI Pharma AB Annual report: Q4 2025 - Filings
- 1 year ago - ODI Pharma AB Quarterly report: Q4 2025 - Filings